No Data
No Data
IBN Coverage: Clene (NASDAQ: CLNN) Makes Strides in Developing CNM-Au8(R) to Address Neurodegenerative Conditions
IBN Coverage: Clene (NASDAQ: CLNN) CEO Spotlighted in Recent BioMedWire Podcast Episode
HC Wainwright & Co. Maintains Buy on Clene, Adjusts Price Target To $31
HC Wainwright & Co. Maintains Buy on Clene, Adjusts Price Target To $31 (1-20 Reverse Stock Split)
IBN Coverage: Clene (NASDAQ: CLNN) Releases Q2 2024 Financial Results, Provides Updates
Buy Rating Justified for Clene Amidst Promising ALS Trial Results and Potential Accelerated FDA Approval
No Data
This_Guy : day traders?